HC Wainwright cut shares of Acer Therapeutics (NASDAQ:ACER – Free Report) from a buy rating to a neutral rating in a research report released on Tuesday morning, Marketbeat reports. HC Wainwright also issued estimates for Acer Therapeutics’ Q3 2023 earnings at ($0.12) EPS, Q4 2023 earnings at ($0.06) EPS and FY2024 earnings at $0.00 EPS. […]
Roth Capital reaffirmed their neutral rating on shares of Acer Therapeutics (NASDAQ:ACER – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $1.50 price target on the biopharmaceutical company’s stock. Separately, Roth Mkm cut Acer Therapeutics from a buy rating to a neutral rating and set a $1.50 target price […]
Roth Mkm lowered shares of Acer Therapeutics (NASDAQ:ACER – Free Report) from a buy rating to a neutral rating in a research note published on Friday, MarketBeat reports. Roth Mkm currently has $1.50 price target on the biopharmaceutical company’s stock. Acer Therapeutics Trading Down 10.9 % Acer Therapeutics stock opened at $1.14 on Friday. The […]
Shares of Acer Therapeutics Inc. (NASDAQ:ACER – Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.58 and traded as low as $0.92. Acer Therapeutics shares last traded at $0.94, with a volume of 69,983 shares changing hands. Analyst Ratings Changes Separately, HC […]
SVB Wealth LLC purchased a new position in Acer Therapeutics Inc. (NASDAQ:ACER – Get Rating) in the fourth quarter, HoldingsChannel reports. The firm purchased 11,500 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Separately, Renaissance Technologies LLC lifted its position in Acer Therapeutics by 216.8% in the second quarter. Renaissance Technologies LLC now […]